Psychedelic Bulletin #110 – Psychedelics Docuseries Comes to Netflix; DEA Schedules Public Hearing on Banning 5 Psychedelics Post published:July 11, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin #109 – California Decrim. Back on the Agenda; Reanalysis of NEJM Psilocybin vs. Escitalopram Trial; Off-Label = Off the Rails? Post published:July 4, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin #108 – COMPASS Survives Patent Challenges; MindMed Secures Candyflipping IP; Will Psychedelics Companies Protect Access to Abortion for Employees? Post published:June 27, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin #107 – Call for Proposals: Opinions Column; How to Change Your Mind Comes to Netflix Post published:June 18, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin #106 – DMT Study Skips Set and Setting; Cybin Acquires Phase 1 Study; FDA Snubs Seamless Trial Design Post published:June 13, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin #105 – UK Won’t Foot the Bill for Spravato; Another KAP Provider Launches; Canadian Province Decriminalises Possession of MDMA and Other Drugs Post published:June 3, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin #104 – Mydecine CEO Downplays Insider Activity; UC Davis Scores $2.7m to Study Non-hallucinogenic Psychedelics; Oregon Health Authority Adopts Rules Post published:May 27, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin #103 – MAPS Phase 3 Trial On Schedule; Australia’s National Science Agency Working on Psychedelics; Death Spiral Financings Post published:May 22, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin #102 – Our Analysis of MindMed’s LSD for Anxiety Results; Mail-Order Ketamine May Come Under Scrutiny; Our Notes from PSYCH Symposium Post published:May 16, 2022 Post category:Psychedelic Bulletin
Psychedelic Bulletin #101 – Psychedelic R&D in the UK; COMPASS Study Points to Psilocybin for Anorexia Post published:May 6, 2022 Post category:Psychedelic Bulletin